Stoke Therapeutics (STOK) Total Non-Current Liabilities (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Total Non-Current Liabilities of $7.6 million for Q1 2026, down 37.39% year-over-year from $12.1 million in Q1 2025, and down 6.27% quarter-over-quarter from $8.1 million in Q4 2025.
Stoke Therapeutics (STOK) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $7.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 37.39% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (down 37.39% YoY), while the FY2025 annual figure was $8.1 million, up 226.96% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $7.6 million, down from $8.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $53.1 million in Q1 2022, with the low at $2.5 million in Q4 2024.
- The 5-year median for Total Non-Current Liabilities is $29.2 million (2024), against an average of $27.1 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 15832.73% in 2022, then slumped 93.47% in 2024.
- Stoke Therapeutics' Total Non-Current Liabilities stood at $39.8 million in 2022, then retreated by 4.69% to $38.0 million in 2023, then plunged by 93.47% to $2.5 million in 2024, then jumped by 226.96% to $8.1 million in 2025, then fell by 6.27% to $7.6 million in 2026.
- Business Quant data shows STOK's Total Non-Current Liabilities at $7.6 million in Q1 2026, $8.1 million in Q4 2025, and $10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 6.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.49 Mn |
| Mar 31, 2026 | 7.59 Mn |
| Dec 31, 2025 | 8.10 Mn |
| Sep 30, 2025 | 10.43 Mn |
| Jun 30, 2025 | 10.89 Mn |
| Mar 31, 2025 | 12.13 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 11.34 Mn |
| Jun 30, 2024 | 20.55 Mn |
| Mar 31, 2024 | 29.25 Mn |
| Dec 31, 2023 | 37.96 Mn |
| Sep 30, 2023 | 41.69 Mn |
| Jun 30, 2023 | 44.89 Mn |
| Mar 31, 2023 | 36.45 Mn |
| Dec 31, 2022 | 39.82 Mn |
| Sep 30, 2022 | 44.69 Mn |
| Jun 30, 2022 | 49.46 Mn |
| Mar 31, 2022 | 53.06 Mn |
| Dec 31, 2021 | 3.95 Mn |
| Sep 30, 2021 | 4.37 Mn |